Mucinoses: Clinical Trials

16 trials for Mucinoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 terminated. 16 Phase 2, 8 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 216Terminated 16
Phase 18Terminated 8
Phase 31Terminated 1

Follow Mucinoses: new trials by email Literature Review of Mucinoses trials Research Report on Mucinoses

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia
Recifercept - Achondroplasia
Phase 2TerminatedPfizer352021-12-242024-02-08
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
Recifercept - Achondroplasia
Phase 2TerminatedPfizer602020-12-022024-02-15
Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
ABO-102 - MPS IIIA, Sanfilippo Syndrome
Phase 1 / Phase 2TerminatedUltragenyx Pharmaceutical Inc52019-09-182023-07-25
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
rAAV9.CMV.hNAGLU - Mucopolysaccharidosis Type 3 B
Phase 1 / Phase 2TerminatedAbeona Therapeutics, Inc112017-10-162022-05-05
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
SB-318 - MPS I
Phase 1 / Phase 2TerminatedSangamo Therapeutics32017-05-242023-01-26
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
SB-913 - Mucopolysaccharidosis II, MPS II
Phase 1 / Phase 2TerminatedSangamo Therapeutics92017-05-112022-10-25
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
SBC-103 - Mucopolysaccharidosis III, Type B (MPS IIIB), Sanfilippo B
Phase 1 / Phase 2TerminatedAlexion Pharmaceuticals, Inc.32015-10-152018-04-17
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
HGT-1410 - Sanfilippo Syndrome, Mucopolysaccharidosis (MPS)
Phase 2TerminatedShire172015-04-082021-06-11
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
BMN 110 - Mucopolysaccharidosis IVA, Morquio A Syndrome
Phase 2TerminatedBioMarin Pharmaceutical162012-08-012016-01-12
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
BMN 110 - Mucopolysaccharidosis IVA, Morquio A Syndrome
Phase 2TerminatedBioMarin Pharmaceutical252012-04-012016-02-01
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome
Phase 1 / Phase 2TerminatedTalaris Therapeutics Inc.32011-04-012023-04-12
Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
rhHNS-10 mg, rhHNS-45 mg, rhHNS-90 mg - Sanfilippo Syndrome
Phase 1 / Phase 2TerminatedShire122011-03-012021-06-14
A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
BMN 110 - MPS IV A, Mucopolysaccharidosis IVA
Phase 1 / Phase 2TerminatedBioMarin Pharmaceutical202010-11-012015-09-30
Clinical Trial of Growth Hormone in MPS I, II, and VI
Somatropin (DNA origin) - Mucopolysaccharidosis I, Mucopolysaccharidosis II
Phase 2 / Phase 3TerminatedLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center22008-11-012018-09-05
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus - Parkinson's Disease
Phase 2TerminatedNeurologix, Inc.442008-08-012012-02-22
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome
Phase 2TerminatedMasonic Cancer Center, University of Minnesota182008-03-012017-12-28

Narrower conditions

Mucopolysaccharidosis III (6)  ·  Mucopolysaccharidosis IV (5)  ·  Lysosomal Storage Diseases (4)  ·  Mucopolysaccharidosis I (4)  ·  Mucopolysaccharidosis II (3)  ·  Sudden Infant Death (3)  ·  Achondroplasia (2)  ·  Dwarfism (2)  ·  Leukodystrophy, Globoid Cell (2)  ·  Leukodystrophy, Metachromatic (2)  ·  Mucopolysaccharidosis VI (2)  ·  alpha-Mannosidosis (2)  ·  Adrenoleukodystrophy (1)  ·  Aspartylglucosaminuria (1)  ·  Basal Ganglia Diseases (1)

Broader conditions

Connective Tissue Diseases (16)  ·  Skin and Connective Tissue Diseases (16)  ·  Carbohydrate Metabolism, Inborn Errors (15)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15)  ·  Metabolic Diseases (15)  ·  Nutritional and Metabolic Diseases (15)  ·  Genetic Diseases, Inborn (14)  ·  Metabolism, Inborn Errors (14)  ·  Mucopolysaccharidoses (14)  ·  Lysosomal Storage Diseases (11)  ·  Nervous System Diseases (4)  ·  Bone Diseases, Developmental (3)  ·  Death (3)  ·  Death, Sudden (3)

Interventions

GALNS protein, human (3)  ·  Chondroitinases and Chondroitin Lyases (2)  ·  Enzyme Replacement Therapy (2)  ·  Galns protein, mouse (2)  ·  Stem Cell Transplantation (2)  ·  Sulfatases (2)  ·  Alemtuzumab (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Cyclophosphamide (1)  ·  Growth Hormone (1)  ·  Human Growth Hormone (1)

Sponsors

BioMarin Pharmaceutical (3)  ·  Pfizer (2)  ·  Sangamo Therapeutics (2)  ·  Shire (2)  ·  Abeona Therapeutics, Inc (1)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Neurologix, Inc. (1)  ·  Talaris Therapeutics Inc. (1)  ·  Ultragenyx Pharmaceutical Inc (1)

Countries

United States (13)  ·  United Kingdom (6)  ·  Spain (5)  ·  Germany (4)  ·  Australia (3)  ·  Italy (3)  ·  Belgium (2)  ·  Denmark (2)  ·  France (2)  ·  Netherlands (2)  ·  Portugal (2)  ·  Canada (1)  ·  Japan (1)

Top investigators

Adam Shaywitz, MD PhD (1)  ·  Celeste Decker, M.D. (1)  ·  Celeste Decker, MD (1)  ·  Lynda E Polgreen, M.D. (1)  ·  Paul Orchard, MD (1)  ·  Suzanne T Ildstad, MD (1)

Results publications

PMID 36299240, PMID 21419704, PMID 21586746, PMID 22547151, PMID 25421091, PMID 28405611, PMID 29159458, PMID 29526614, PMID 32278382, PMID 32884151, PMID 34600820, PMID 38685585

NIH funding

2014 (1), 2015 (1), 2018 (1)